Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Brett

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Clinical Obesity|May 21, 2016
Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight managementR L Kolotkin, K Fujioka, M L Wolden, et al.
Development and Psychopathology|May 23, 2015
Using cross-species comparisons and a neurobiological framework to understand early social deprivation effects on behavioral developmentZoë H Brett, Kathryn L Humphreys, Alison S Fleming, et al.
Social Science & Medicine (1982)|April 2, 2013
Neighborhood disorder and telomeres: connecting children's exposure to community level stress and cellular responseKatherine P Theall, Zoë H Brett, Elizabeth A Shirtcliff, et al.
Biotechnology and Bioengineering|July 23, 2009
A predictive high-throughput scale-down model of monoclonal antibody production in CHO cellsRachel Legmann, H Brett Schreyer, Rodney G Combs, et al.
Pediatrics|June 18, 2014
The association of telomere length with family violence and disruptionStacy S Drury, Emily Mabile, Zoë H Brett, et al.
Journal of Virology|April 10, 1999
Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseaseK A Staskus, R Sun, G Miller, et al.
Lancet (London, England)|June 12, 2009
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)John B Buse, Julio Rosenstock, Giorgio Sesti, et al.
The Journal of Clinical Endocrinology and Metabolism|April 1, 2011
Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trialsJohn B Buse, Alan Garber, Julio Rosenstock, et al.
International Journal of Behavioral Development|February 10, 2015
A neurogenetics approach to defining differential susceptibility to institutional careZoe H Brett, Margaret Sheridan, Kate Humphreys, et al.
Biotechnology and Bioengineering|January 15, 2010
Novel micro-bioreactor high throughput technology for cell culture process development: Reproducibility and scalability assessment of fed-batch CHO culturesAshraf Amanullah, Jose Manuel Otero, Mark Mikola, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Clinical Obesity|May 21, 2016
Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight managementR L Kolotkin, K Fujioka, M L Wolden, et al.
Development and Psychopathology|May 23, 2015
Using cross-species comparisons and a neurobiological framework to understand early social deprivation effects on behavioral developmentZoë H Brett, Kathryn L Humphreys, Alison S Fleming, et al.
Social Science & Medicine (1982)|April 2, 2013
Neighborhood disorder and telomeres: connecting children's exposure to community level stress and cellular responseKatherine P Theall, Zoë H Brett, Elizabeth A Shirtcliff, et al.
Biotechnology and Bioengineering|July 23, 2009
A predictive high-throughput scale-down model of monoclonal antibody production in CHO cellsRachel Legmann, H Brett Schreyer, Rodney G Combs, et al.
Pediatrics|June 18, 2014
The association of telomere length with family violence and disruptionStacy S Drury, Emily Mabile, Zoë H Brett, et al.
Journal of Virology|April 10, 1999
Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseaseK A Staskus, R Sun, G Miller, et al.
Lancet (London, England)|June 12, 2009
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)John B Buse, Julio Rosenstock, Giorgio Sesti, et al.
The Journal of Clinical Endocrinology and Metabolism|April 1, 2011
Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trialsJohn B Buse, Alan Garber, Julio Rosenstock, et al.
International Journal of Behavioral Development|February 10, 2015
A neurogenetics approach to defining differential susceptibility to institutional careZoe H Brett, Margaret Sheridan, Kate Humphreys, et al.
Biotechnology and Bioengineering|January 15, 2010
Novel micro-bioreactor high throughput technology for cell culture process development: Reproducibility and scalability assessment of fed-batch CHO culturesAshraf Amanullah, Jose Manuel Otero, Mark Mikola, et al.
Pageof 4